A monoclonal antibody specifically binds to human B7.1 antigen and is capable of inhibiting the binding of B7.1 to a CD28 receptor and is not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. This antibody may be used for the treatment of Crohn's disease.